Indrani Lall Franchini Sells 2,605 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) EVP Indrani Lall Franchini sold 2,605 shares of the business’s stock in a transaction that occurred on Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total value of $307,728.65. Following the completion of the sale, the executive vice president now owns 29,304 shares of the company’s stock, valued at approximately $3,461,681.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of ALXN traded down $0.19 during mid-day trading on Friday, hitting $123.15. 1,314,643 shares of the company’s stock traded hands, compared to its average volume of 1,093,766. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.74 and a current ratio of 3.16. Alexion Pharmaceuticals, Inc. has a 1 year low of $102.10 and a 1 year high of $140.77. The stock has a market capitalization of $27.52 billion, a PE ratio of 23.87, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the previous year, the firm earned $1.44 earnings per share. The business’s revenue was up 19.5% compared to the same quarter last year. Research analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.82 EPS for the current fiscal year.

ALXN has been the subject of several recent research reports. BidaskClub downgraded Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. Stifel Nicolaus boosted their price objective on Alexion Pharmaceuticals from $130.00 to $136.00 and gave the company a “hold” rating in a research report on Tuesday, September 25th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, October 5th. Citigroup boosted their price objective on Alexion Pharmaceuticals from $173.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, September 25th. Finally, ValuEngine downgraded Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 4th. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $161.50.

A number of hedge funds have recently modified their holdings of ALXN. Jennison Associates LLC grew its stake in Alexion Pharmaceuticals by 43.1% in the third quarter. Jennison Associates LLC now owns 8,627,536 shares of the biopharmaceutical company’s stock worth $1,199,314,000 after purchasing an additional 2,599,414 shares during the period. FMR LLC grew its stake in Alexion Pharmaceuticals by 8.1% in the third quarter. FMR LLC now owns 21,096,993 shares of the biopharmaceutical company’s stock worth $2,932,693,000 after purchasing an additional 1,581,376 shares during the period. Iridian Asset Management LLC CT grew its stake in Alexion Pharmaceuticals by 14,950.7% in the second quarter. Iridian Asset Management LLC CT now owns 1,496,192 shares of the biopharmaceutical company’s stock worth $185,752,000 after purchasing an additional 1,486,251 shares during the period. American Century Companies Inc. grew its stake in Alexion Pharmaceuticals by 164.2% in the third quarter. American Century Companies Inc. now owns 1,904,296 shares of the biopharmaceutical company’s stock worth $264,716,000 after purchasing an additional 1,183,476 shares during the period. Finally, Advisors Asset Management Inc. grew its stake in Alexion Pharmaceuticals by 7,677.7% in the second quarter. Advisors Asset Management Inc. now owns 1,155,454 shares of the biopharmaceutical company’s stock worth $2,288,000 after purchasing an additional 1,140,598 shares during the period. 96.62% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Indrani Lall Franchini Sells 2,605 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.com-unik.info/2018/12/01/indrani-lall-franchini-sells-2605-shares-of-alexion-pharmaceuticals-inc-alxn-stock.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Recommended Story: Outstanding Shares and The Effect on Share Price

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit